On October 22, 2019 Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, reported that it will present data on its wholly-owned, CBL-B small molecule drug development program at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 34th Annual Meeting (SITC 2019) (Press release, Nurix Therapeutics, OCT 22, 2019, View Source [SID1234542409]). SITC (Free SITC Whitepaper) is being held on November 6-10, 2019 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Title: Pharmacological evaluation of the ubiquitin ligase CBL-B as a small molecule, tumor immunotherapy target
Poster #: P669
Date: Friday, November 8, 2019
Time: 7:00 a.m. – 8:00 p.m. EST